Cargando…

Plasma soluble tumor necrosis factor receptor I as a biomarker of lupus nephritis and disease activity in systemic lupus erythematosus patients

OBJECTIVES: The goal of our study was to evaluate the potential role of sTNF-RI as a biomarker of renal involvement in SLE patients and active SLE. METHODS: The study sample consisted of two cohorts. The discovery cohort included 16 SLE patients without renal involvement (non-LN), 60 lupus nephritis...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xin-ran, Qi, Yuan-yuan, Zhao, Ya-fei, Cui, Yan, Zhao, Zhan-zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035946/
https://www.ncbi.nlm.nih.gov/pubmed/36946374
http://dx.doi.org/10.1080/0886022X.2023.2174355
_version_ 1784911530864672768
author Liu, Xin-ran
Qi, Yuan-yuan
Zhao, Ya-fei
Cui, Yan
Zhao, Zhan-zheng
author_facet Liu, Xin-ran
Qi, Yuan-yuan
Zhao, Ya-fei
Cui, Yan
Zhao, Zhan-zheng
author_sort Liu, Xin-ran
collection PubMed
description OBJECTIVES: The goal of our study was to evaluate the potential role of sTNF-RI as a biomarker of renal involvement in SLE patients and active SLE. METHODS: The study sample consisted of two cohorts. The discovery cohort included 16 SLE patients without renal involvement (non-LN), 60 lupus nephritis (LN) patients and 21 healthy controls (HCs) and the replication cohort included 18 SLE non-LN patients, 116 LN patients and 36 HCs. RESULTS: The sTNF-RI levels differed significantly in the discovery cohort. The plasma sTNF-RI levels were higher in LN patients than in non-LN patients (p = .009) and HCs (p = 4 × 10(−6)). Plasma sTNF-RI levels were significantly higher in non-LN patients than in HCs (p = .03). The finding was confirmed in independent replication cohort (LNs vs. non-LN, p = 4.053 × 10(−7); LNs vs. HCs, p = 2.395 × 10(−18); non-LN vs. HCs, p = 2.51 × 10(−4)). The plasma sTNF-RI levels were associated with disease activity, renal function in SLE patients and urine protein in LN patients. The multivariate analysis revealed that high sTNF-RI was an independent risk factor for renal involvement. The multivariate logistic regression results suggested that high TNF-RI, high systolic blood pressure, high serum creatinine, low C4 and positive anti-dsDNA were independent risks of active SLE patients. A nomogram was constructed based on the results of multivariate logistic regression analysis and it was practical in predicting the risk of the active SLE patients. Immunohistochemistry suggested that the expression of TNF-RI in the kidney was increased. CONCLUSIONS: Plasma sTNF-RI might be a good biomarker of renal involvement and disease activity in SLE patients.
format Online
Article
Text
id pubmed-10035946
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-100359462023-03-24 Plasma soluble tumor necrosis factor receptor I as a biomarker of lupus nephritis and disease activity in systemic lupus erythematosus patients Liu, Xin-ran Qi, Yuan-yuan Zhao, Ya-fei Cui, Yan Zhao, Zhan-zheng Ren Fail Clinical Study OBJECTIVES: The goal of our study was to evaluate the potential role of sTNF-RI as a biomarker of renal involvement in SLE patients and active SLE. METHODS: The study sample consisted of two cohorts. The discovery cohort included 16 SLE patients without renal involvement (non-LN), 60 lupus nephritis (LN) patients and 21 healthy controls (HCs) and the replication cohort included 18 SLE non-LN patients, 116 LN patients and 36 HCs. RESULTS: The sTNF-RI levels differed significantly in the discovery cohort. The plasma sTNF-RI levels were higher in LN patients than in non-LN patients (p = .009) and HCs (p = 4 × 10(−6)). Plasma sTNF-RI levels were significantly higher in non-LN patients than in HCs (p = .03). The finding was confirmed in independent replication cohort (LNs vs. non-LN, p = 4.053 × 10(−7); LNs vs. HCs, p = 2.395 × 10(−18); non-LN vs. HCs, p = 2.51 × 10(−4)). The plasma sTNF-RI levels were associated with disease activity, renal function in SLE patients and urine protein in LN patients. The multivariate analysis revealed that high sTNF-RI was an independent risk factor for renal involvement. The multivariate logistic regression results suggested that high TNF-RI, high systolic blood pressure, high serum creatinine, low C4 and positive anti-dsDNA were independent risks of active SLE patients. A nomogram was constructed based on the results of multivariate logistic regression analysis and it was practical in predicting the risk of the active SLE patients. Immunohistochemistry suggested that the expression of TNF-RI in the kidney was increased. CONCLUSIONS: Plasma sTNF-RI might be a good biomarker of renal involvement and disease activity in SLE patients. Taylor & Francis 2023-03-22 /pmc/articles/PMC10035946/ /pubmed/36946374 http://dx.doi.org/10.1080/0886022X.2023.2174355 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Clinical Study
Liu, Xin-ran
Qi, Yuan-yuan
Zhao, Ya-fei
Cui, Yan
Zhao, Zhan-zheng
Plasma soluble tumor necrosis factor receptor I as a biomarker of lupus nephritis and disease activity in systemic lupus erythematosus patients
title Plasma soluble tumor necrosis factor receptor I as a biomarker of lupus nephritis and disease activity in systemic lupus erythematosus patients
title_full Plasma soluble tumor necrosis factor receptor I as a biomarker of lupus nephritis and disease activity in systemic lupus erythematosus patients
title_fullStr Plasma soluble tumor necrosis factor receptor I as a biomarker of lupus nephritis and disease activity in systemic lupus erythematosus patients
title_full_unstemmed Plasma soluble tumor necrosis factor receptor I as a biomarker of lupus nephritis and disease activity in systemic lupus erythematosus patients
title_short Plasma soluble tumor necrosis factor receptor I as a biomarker of lupus nephritis and disease activity in systemic lupus erythematosus patients
title_sort plasma soluble tumor necrosis factor receptor i as a biomarker of lupus nephritis and disease activity in systemic lupus erythematosus patients
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035946/
https://www.ncbi.nlm.nih.gov/pubmed/36946374
http://dx.doi.org/10.1080/0886022X.2023.2174355
work_keys_str_mv AT liuxinran plasmasolubletumornecrosisfactorreceptoriasabiomarkeroflupusnephritisanddiseaseactivityinsystemiclupuserythematosuspatients
AT qiyuanyuan plasmasolubletumornecrosisfactorreceptoriasabiomarkeroflupusnephritisanddiseaseactivityinsystemiclupuserythematosuspatients
AT zhaoyafei plasmasolubletumornecrosisfactorreceptoriasabiomarkeroflupusnephritisanddiseaseactivityinsystemiclupuserythematosuspatients
AT cuiyan plasmasolubletumornecrosisfactorreceptoriasabiomarkeroflupusnephritisanddiseaseactivityinsystemiclupuserythematosuspatients
AT zhaozhanzheng plasmasolubletumornecrosisfactorreceptoriasabiomarkeroflupusnephritisanddiseaseactivityinsystemiclupuserythematosuspatients